XRK3F2 NEW
| Price | $34 | $79 | $122 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: XRK3F2 | CAS No.: 2375193-43-2 |
| Purity: 99.12% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | XRK3F2 |
| Description | XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo. |
| In vitro | XRK3F2 inhibits p62-ZZ domain signaling and rescues Myeloma-induced Gfi1-driven epigenetic repression of the Runx2 gene in pre-osteoblasts to overcome differentiation suppression. XRK3F2 prevents MM-induced upregulation of Gfi1 and repression of the Runx2 gene when present in MM-preOB co-cultures. p62-ZZ-domain blocking by XRK3F2 prevents MM conditioned media and TNF plus IL7-mediated Gfi1 mRNA upregulation and the concomitant Runx2 repression. XRK3F2 decreased MM-induced GFI1 occupancy at the Runx2-P1 promoter and prevented recruitment of HDAC1, thus preserving the transcriptionally permissive chromatin mark H3K9ac on Runx2 and allowing osteogenic differentiation[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (573.54 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.18 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (22.94 mM), Suspension. H2O : 0.8 mg/mL (1.84 mM), Sonication is recommended. |
| Keywords | XRK-3F2 | XRK3F2 | P62-ZZ domain | p62-ZZ |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Autophagy Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $34.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY